GlassScriptPrepare for your visit
Mian A Jan
Cardiovascular Disease · West Chester, PA · NPI 1487693537
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$20,394.22
in general payments reported to CMS, 2019-2025 · $710 in 2025
The $710 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Who reported paying
General payments only, top 6 by amount.
- Astrazeneca Pharmaceuticals LP $14,567.04
- Abbott Laboratories $1,346.26
- Boston Scientific Corporation $770.60
- Amgen INC. $644.19
- Janssen Pharmaceuticals, INC $528.12
- Novartis Pharmaceuticals Corporation $452.66
Drugs and devices associated with these payments
Farxiga Leqvio Repatha Remede System Furoscix Xarelto Eliquis Camzyos Hillrom - Cardiac Ambulatory Monitor Watchman Flx Entresto Afrezza
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Mian Jan listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/22271/mian-a-jan